The international classification of retinoblastoma predicts chemoreduction success
The international classification of retinoblastoma predicts chemoreduction success
复制标题
DOI：
10.1016/j.ophtha.2006.06.018
复制
发表时间：
2006-12-01
期刊：
影响因子：
13.7
通讯作者：
Shields, Jerry A.
中科院分区：
文献类型：
--
作者：
Shields, Carol L.;Mashayekhi, Arman;Shields, Jerry A.
目的：评价国际视网膜母细胞瘤分类在预测视网膜母细胞瘤化疗成功的可靠性。设计：非对比性介入病例系列。参与者：连续249只眼。方法：所有患者均接受视网膜母细胞瘤治疗，并根据国际视网膜母细胞瘤分类标准进行分类：A组为视网膜母细胞瘤3 mm、黄斑部或少量视网膜下积液；C组为视网膜母细胞瘤内有局限性颗粒物；D组为视网膜母细胞瘤弥漫性颗粒；E组为大量视网膜母细胞瘤需行核化治疗的眼。结果：249只眼中，A组23只眼(9%)，B组96只眼(39%)，C组21只眼(8%)，D组109只眼(44%)。治疗成功率A组为100%，B组为93%，C组为90%，D组为47%。结论：ICRB有助于预测视网膜母细胞瘤CRD的治疗成功率。为了挽救更多的D组眼，有必要采取额外的治疗方法。
Purpose: To evaluate the reliability of the International Classification of Retinoblastoma (ICRB) for predicting treatment success with chemoreduction (CRD).Design: Noncomparative interventional case series.Participants: Two hundred forty-nine consecutive eyes.Methods: All eyes were treated with CRD and were classified according to the ICRB: group A included those eyes with retinoblastoma 3 mm, macular location, or minor subretinal fluid; group C included those eyes with retinoblastoma with localized seeds; group D included those eyes with retinoblastoma with diffuse seeds; group E included those eyes with massive retinoblastoma necessitating enucleation. The CRD regimen included vincristine, etoposide, and carboplatin for 6 cycles plus local consolidation with thermotherapy or cryotherapy.Main Outcome Measure: Chemoreduction success, defined as avoidance of external beam radiotherapy or enucleation.Results: Of the 249 eyes, 23 (9%) were in group A, 96 (39%) were in group B, 21 (8%) were in group C, and 109 (44%) were in group D. In this series, group E eyes were managed with enucleation. Treatment success was achieved in 100% of group A, 93% of group B, 90% of group C, and 47% of group D eyes.Conclusions: The ICRB can be of assistance in predicting CRD success for retinoblastoma. Additional treatment methods are necessary to salvage more group D eyes.